LEIDOS BIOMEDICAL RESEARCH INC

Leidos Biomedical Research Inc. specializes in advanced biomedical research and development, delivering mission-critical scientific support to federal health agencies. Their core capabilities encompass translational data systems, proteomic analysis, antibody characterization, vaccine development for emerging pathogens, and immune oncology data harmonization. The contractor provides end-to-end technical execution for complex life science initiatives, including clinical data commons infrastructure, high-throughput biological assay platforms, and bioinformatics tool development. They excel in integrating large-scale biomedical datasets, supporting vaccine research pipelines, and maintaining secure, compliant research environments for high-consequence pathogens. Their technical expertise spans computational biology, immunoinformatics, and laboratory information management systems, with a demonstrated ability to manage mission-essential research operations under stringent regulatory standards. The company maintains an exclusive, long-standing relationship with the Department of Health and Human Services, primarily supporting agencies such as the National Cancer Institute, NIAID, and ARPA-H. Their work includes operational task orders for research facilities, data infrastructure modernization, and targeted biomedical R&D programs, indicating deep institutional trust and integration within HHS’s scientific ecosystem. Their primary industry focus is in research and development within the physical, engineering, and life sciences, with a distinct specialization in biomedical innovation. They operate at the intersection of laboratory science and data-driven discovery, serving as a key enabler for federal biomedical priorities in infectious disease, cancer immunotherapy, and precision health. Leidos Biomedical Research Inc. is a 2L entity headquartered in Frederick, Maryland, with a focused presence in federal biomedical research hubs. While no formal certifications are listed, their sustained engagement with HHS and execution of high-complexity, mission-critical scientific contracts underscore their credibility and operational maturity within the government life sciences market.